Hundreds of veterans are set to participate in a national clinical trial examining the efficacy of semaglutide, a compound in diabetes and weight-loss drugs like Ozempic, as a treatment for alcohol addiction. The Department of Veterans Affairs (VA) announced the trial recently, targeting a pressing health issue among veterans. VA statistics reveal that over 400,000 veterans in the U.S. have an alcohol use disorder (AUD).
The trial, named the Cessation or Reduction of Alcohol Consumption in Veterans, explores the potential of GLP-1 receptor agonists to influence addictive behaviors. These medications act similarly to hormones that manage blood sugar, appetite, and brain reward pathways.
This clinical trial reflects medical research that VA is uniquely situated to launch, and is aimed directly at benefitting Veterans, noted VA Secretary Doug Collins. By investigating emerging treatments like GLP-1 for AUD, we hope to broaden the treatment options for Veterans in their health and recovery quest.
Structure of the VA Alcohol Use Disorder Trial
The trial plans to enroll over 600 veterans at 18 VA medical centers nationwide. Such trials are vital for assessing treatment effectiveness within specific patient segments, with strict monitoring for safety and side effects.
Trial Details:
- Participant Criteria: Eligible participants will be between ages 18 and 80 and must have a moderate or severe AUD diagnosis.
- Evaluation Metrics: Participants will receive weekly semaglutide or placebo injections during a 24-week span, followed by a safety follow-up.
- Timeline: Participant recruitment started on July 28. Researchers will monitor changes in alcohol consumption, health, and quality of life to evaluate the treatment’s potential.
Veterans looking for trial details can contact their local VA medical center or search ClinicalTrials.gov for information.
The trial follows an observational study of U.S. veterans with Type 2 diabetes that found those on GLP-1 medications had lower alcohol and substance use disorder rates than those on other treatments. Additionally, GLP-1 users had fewer emergency department visits and hospitalizations for existing substance challenges. Since the initial study did not establish causation, the controlled trial aims to evaluate semaglutide’s effectiveness.
The VA advises veterans against self-medicating with GLP-1 drugs or replacing established AUD treatments. Veterans should consult healthcare providers before making any treatment changes.
Participating VA Medical Centers
- Ann Arbor VA Health Care System — Ann Arbor, Michigan
- Charles George VA Medical Center — Asheville, North Carolina
- Durham VA Medical Center — Durham, North Carolina
- Edward Hines Jr. VA Hospital — Hines, Illinois
- George E. Wahlen VA Medical Center — Salt Lake City
- Joseph Maxwell Cleland Atlanta VA Medical Center — Decatur, Georgia
- Louis Stokes Cleveland VA Medical Center — Cleveland
- Michael E. DeBakey VA Medical Center — Houston
- Minneapolis VA Medical Center — Minneapolis
- Orlando VA Medical Center — Orlando, Florida
- Palo Alto VA Medical Center — Palo Alto, California
- Philadelphia VA Healthcare System — Philadelphia
- Portland VA Medical Center — Portland, Oregon
- Tibor Rubin VA Medical Center — Long Beach, California
- VA Greater Los Angeles Health Care System — Los Angeles
- VA North Texas Health Care System — Dallas
- VA Puget Sound Health Care System — Seattle
- William S. Middleton Memorial Veterans Hospital — Madison, Wisconsin
The Challenge of Alcohol Use Disorder Among Veterans
Alcohol use disorder is a condition where individuals struggle to control drinking despite negative impacts on social, occupational, or health aspects. It ranges from mild to severe.
A representative study by the VA highlights that 40.8% of veterans have been diagnosed with AUD at least once. More than 10.5% met the criteria for probable AUD in the past year, with higher rates among younger veterans.
Alcohol misuse can coincide with post-traumatic stress disorder (PTSD) and other mental health issues. Veterans with PTSD are twice as likely to face alcohol problems compared to those without a PTSD history, according to the VA’s National Center for PTSD.
Veterans diagnosed with both probable AUD and PTSD face heightened risks of depression, anxiety, and suicidal tendencies compared to those with AUD alone. The VA emphasizes that both conditions can be concurrently managed with therapy, medication, or combining approaches.